Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
Gliclazide is a 'second generation' oral hypoglycaemic agent. The particular interest with this drug is that it has shown certain effects on the blood for which it is hoped there may be some clinical benefit in diabetic angiopathies. Both in animal and human studies it has demonstrated a reduction in platelet adhesiveness and aggregation, whilst possible enhancement of platelet metabolism, reduction of coagulant factors, as well as increased fibrinolytic activity, are still being investigated. Initial trials have suggested that gliclazide therapy may reverse or at least slow down the progression of diabetic retinopathy. However, a few additional well-designed long term controlled studies are needed to confirm these findings, and to clarify whether any beneficial effect on diabetic retinopathy is unique to gliclazide or also occurs with other oral hypoglycaemic drugs. Both newly diagnosed maturity onset diabetics as well as those previously treated with sulphonylureas respond well to gliclazide therapy. In the small comparative studies which have been reported, gliclazide was of comparable efficacy to other oral hypoglycaemic agents.
D000042:Absorption; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001792:Blood Platelets / Q000502:physiology*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy; D004347:Drug Interactions; D011464:Epoprostenol / Q000096:biosynthesis; D005342:Fibrinolysis / Q000187:drug effects; D005907:Gliclazide / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008055:Lipids / Q000097:blood; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D012098:Reproduction / Q000187:drug effects; D013453:Sulfonylurea Compounds / Q000494:pharmacology*; D014018:Tissue Distribution
D001786:Blood Glucose; D008055:Lipids; D013453:Sulfonylurea Compounds; D011464:Epoprostenol; D005907:Gliclazide